Estradiol

Limits on what this shows

• Key negative/null findings: None identified; all preclinical signals point the same, protective direction. This is itself a limitation (no attempt found to falsify the finding) as much as a reassurance.
• At-risk subgroups: Not applicable; this is not a deficiency-risk entry.
• Counter-evidence: None found contradicting the direction; human confirmation is simply absent.

Regulatory status

Not addressed in the label.

Population evidence

No human clinical study identified. Preclinical: "17beta-Estradiol Directly Lowers Mitochondrial Membrane Microviscosity and Improves Bioenergetic Function in Skeletal Muscle" (Torres et al, Cell Metabolism, 2018); "Estradiol stimulates mitochondrial biogenesis and adiponectin expression in skeletal muscle" (Capllonch-Amer et al, J Endocrinol, 2014); "Role of estrogen on skeletal muscle mitochondrial function in ovariectomized rats" (Cavalcanti-de-Albuquerque et al, J Appl Physiol, 2014). These were identified and confirmed via live PubMed search-listing metadata (title, author, journal, year); full abstracts could not be opened during this review due to repeated PubMed rate-limiting, so exact species/sample-size detail beyond what each title states is not independently confirmed here.

Mechanism

Estrogen-receptor-alpha-mediated effects on mitochondrial membrane biophysics and biogenesis signaling in skeletal muscle, consistent with ERalpha's documented mitochondrial localization in muscle.

Counter-evidence held on record

This is a reverse-direction (protective-looking), preclinical-only finding. It should not be marketed as a proven human energy or mitochondrial benefit, and it does not license any supplement claim.

Limits on what this shows

• Key negative/null findings: Estradiol arms (oral and transdermal) were the null finding here; this is itself the main evidence.
• At-risk subgroups: Not established; findings apply to healthy postmenopausal women at studied doses.
• Counter-evidence: None found contradicting this direction for estradiol specifically.

Regulatory status

Not addressed in the label.

Population evidence

Same 45-woman, 3-arm, 3-month study as the copper entry (Wakatsuki et al): derivatives of reactive oxygen metabolites (d-ROMs) rose significantly with CEE but not with oral or transdermal estradiol.

Mechanism

Proposed link is the same hepatic-ceruloplasmin/copper pathway: the study authors propose that CEE's copper-elevating effect promotes free-radical generation via Fenton chemistry, and that estradiol's lack of a copper effect at clinical dose is why it also showed no oxidative-stress increase. This overlaps mechanistically with the Copper entry above (see Overlap map).

Counter-evidence held on record

A single 3-month RCT in 45 women; not a basis for either an antioxidant-supplement claim or a warning. This entry primarily exists to correct the "estrogen causes oxidative stress" circulating claim (see Fails Verification).

Limits on what this shows

• Key negative/null findings: The NHANES ferritin finding runs opposite to what hepcidin suppression alone would predict (hepcidin suppression should favor higher, not lower, iron stores), which the study's own authors flagged as evidence of a homeostatic hormonal iron-control pathway rather than a simple depletion or accumulation story.
• At-risk subgroups: Patients with hereditary hemochromatosis or other iron-overload conditions, where any retention-favoring mechanism is the relevant caution, not depletion.
• Counter-evidence: A separate mechanistic review (eLife 2024) modeling ovariectomized atherosclerotic mice found that estradiol's interaction with iron is context-dependent: early postmenopause it preserves estrogen-receptor-alpha signaling, but with age-related iron accumulation it can instead degrade the receptor, worsening atherosclerosis. This is a cardiovascular-signaling finding, not a direct iron-status finding, and is not used to grade iron status itself.

Regulatory status

Not addressed in the estradiol label; no iron-related warning or interaction listed.

Population evidence

NHANES 1999-2000 cross-sectional analysis, women 50+ (n=1,066): current HRT use associated with lower ferritin (beta = -34.13, p=0.0002), independent of hysterectomy/bleeding status. Formulation not specified as estradiol versus conjugated equine estrogen versus other; treated here as class-level (Tier C) for this drug.

Mechanism

Named and direct: 17beta-estradiol suppresses hepcidin transcription via an estrogen-responsive element half-site, shown in human hepatocyte cell lines (HuH7, HepG2) and in wild-type and Hfe-knockout mice given estradiol directly (Xu et al, Endocrinology 2012). A human physiology study (PLOS ONE 2016) found hepcidin-25 fell about 40% (median 4.85 to 1.43 ng/mL, p<0.01) during gonadotropin-stimulated high endogenous-estrogen states, supporting the direction but using endogenous, not exogenous, estrogen.

Counter-evidence held on record

This is a direction-uncertain, mechanism-level signal, not a confirmed deficiency and not a confirmed excess. Because the strongest mechanistic data point toward increased iron retention, iron supplementation should not be added on the basis of this drug alone, and patients with hemochromatosis or other iron-overload risk should not assume estradiol is iron-neutral without monitoring.

Limits on what this shows

• Key negative/null findings: Clinical-dose oral and transdermal estradiol produced no significant copper or ceruloplasmin change in the only drug-specific RCT identified, directly contradicting a simple "estrogen raises copper" narrative at therapeutic exposure.
• At-risk subgroups: Patients with Wilson disease or other copper-handling disorders, for whom copper status should be individually assessed rather than assumed unaffected, given the mechanistic plausibility and the animal/mixed-cohort signal even though the direct RCT was null.
• Counter-evidence: The Wakatsuki RCT is the direct counter-evidence to the animal and cross-sectional data; it used the specific drug and clinical dosing and route, and it is weighted more heavily here than the rat and mixed-cohort studies.

Regulatory status

Not addressed in the estradiol label.

Population evidence

RCT-adjacent controlled comparison, 45 postmenopausal Japanese women in three groups (oral estradiol 1.0 mg/day, transdermal estradiol 50 mcg/day patch, or conjugated equine estrogen), 3 months (Wakatsuki et al): CEE significantly raised plasma copper, ceruloplasmin, and the copper/zinc ratio; oral and transdermal estradiol showed no significant change in either. A separate cross-sectional study of 384 healthy Canadian adults found oral-contraceptive or estrogen-replacement-therapy use (formulation not specified, mixed cohort) significantly raised serum copper and ceruloplasmin, with no effect on Cu,Zn-superoxide dismutase activity.

Mechanism

Named: estrogen receptor-mediated induction of hepatic ceruloplasmin synthesis, the same hepatic binding-protein mechanism that raises CBG (see PK basis). Directly demonstrated with estradiol-17beta in rats (Sunderman et al, 1971): subcutaneous estradiol-17beta 50 mcg/day for 16 days produced a 3-fold increase in serum ceruloplasmin and copper, a supraphysiologic injected dose far above therapeutic HRT exposure.

Counter-evidence held on record

Routine copper monitoring is not supported for standard-dose oral or transdermal estradiol by the direct evidence. The theoretical concern applies mainly to supraphysiologic dosing or to patients with copper-storage disorders. This entry does not support copper supplementation or restriction in either direction for typical use.

Limits on what this shows

• Key negative/null findings: None found; all identified estradiol/HRT-microbiome data point toward restoration of a premenopausal-like pattern rather than disruption.
• At-risk subgroups: Not established; this is not a deficiency-risk entry.
• Counter-evidence: Sample size is small (n=31 total, 17 MHT+) and mixes estradiol formulations with tibolone (a synthetic steroid, not estradiol), which bounds confidence.

Regulatory status

Not addressed in the label.

Population evidence

Frontiers in Medicine, 2025 (DOI 10.3389/fmed.2025.1682925): postmenopausal women, MHT+ (n=17: 2 transdermal estradiol gel, 13 oral estradiol/dydrogesterone [Femostone 1/10], 2 tibolone) versus MHT- (n=14). MHT+ had significantly higher alpha diversity (Ace, Chao, Sobs indices, p<0.05) and higher Coprococcus, Eubacterium_ruminantium_group, and Lachnospiraceae_UCG-010, correlated with lower bone-resorption markers (CTX-1, P1NP) and higher BMD. MHT- had more Escherichia-Shigella, correlated with higher bone turnover. 15 of 17 MHT+ participants were on an estradiol-containing regimen, so this is treated as drug-relevant (Tier B/A-adjacent) rather than pure class extrapolation, though the sample is small and mixed with tibolone.

Mechanism

Not fully elucidated in the source; broader estrogen-gut microbiome literature (Maturitas review; MDPI Nutrients 2026 review, DOI 10.3390/nu18071052) proposes estrogen-receptor signaling and the "estrobolome" (bacterial beta-glucuronidase deconjugating estrogens for reabsorption) as the bidirectional link, with HRT users' microbiota described elsewhere as more similar to premenopausal women (higher Prevotella, lower Escherichia/Klebsiella).

Counter-evidence held on record

Small, bounded, reverse-direction finding. Does not support a probiotic or microbiome-supplement claim tied to estradiol use, and does not support a claim that estradiol harms the microbiome (see Fails Verification).

Limits on what this shows

• Key negative/null findings: None identified.
• At-risk subgroups: Not applicable.
• Counter-evidence: None found.

Regulatory status

Not addressed in the label.

Population evidence

"Estrogen promotes fetal skeletal muscle mitochondrial distribution and ATP synthase activity" (Kim et al, Endocrine, 2024), identified via live PubMed search-listing metadata; full abstract not opened during this review due to rate-limiting, so the fetal/animal model detail is taken from the title only and not independently confirmed beyond that.

Mechanism

Consistent with the mitochondrial-burden entry's ERalpha-mediated mechanism; likely the same underlying signaling pathway measured at the level of ATP synthase activity rather than membrane biophysics.

Counter-evidence held on record

Single preclinical source, title-level confirmation only. Not a basis for a human energy claim. See the Overlap map: this entry and Mitochondrial burden likely share the same underlying estrogen-receptor mechanism in skeletal muscle.

Limits on what this shows

• Why no grade: Both conditions for ungraded were met: no Tier B/C evidence surfaced supporting even a yellow grade, and no circulating consumer claim specific to estradiol and oxygen-carrying capacity was located either, so there was nothing to rebut as white.

Search performed

PubMed search-listing pages ("estrogen replacement therapy hemoglobin plasma volume postmenopausal," "hormone replacement therapy hemoglobin postmenopausal women," "estrogen erythropoiesis erythropoietin women") and a Crossref API query ("estrogen hemoglobin hematocrit postmenopausal hormone therapy") were tried across more than one phrasing; results were either zero-hit or off-topic (glucose/HbA1c-focused studies, not hemoglobin mass or oxygen delivery).

Tooling note

This review's access to PubMed abstract pages, the Crossref REST API, the Europe PMC REST API, and the Semantic Scholar Graph API was repeatedly blocked (reCAPTCHA challenge pages) or rate-limited (HTTP 429) throughout, including on the final attempted query for this category. A later revision should retry this category specifically, since a genuine literature gap cannot be fully distinguished from a tooling gap here.